Novel Ionizable Lipid Nanoparticles for SARS‐CoV‐2 Omicron mRNA Delivery

Jinrong Long,Changxiao Yu,Honglei Zhang,Yiming Cao,Ye Sang,Haitao Lu,Zhen Zhang,Xin Wang,Huanyu Wang,Gengshen Song,Jing Yang,Shengqi Wang
DOI: https://doi.org/10.1002/adhm.202202590
IF: 10
2023-02-01
Advanced Healthcare Materials
Abstract:mRNA‐based therapy has emerged as the most promising nucleic acid therapy in the fight against COVID‐19. However, a safe and efficacious systemic delivery remains a challenge for mRNA therapy. Lipid nanoparticles (LNPs) are currently widely used in mRNA delivery vehicles. Here, series of ionizable LNPs are rationally designed. YK009‐LNP is an optimal delivery platform to carry mRNA. YK009‐LNP exhibited higher mRNA delivery efficiency, a more favorable biodistribution pattern, and better safety than the approved MC3‐LNP. In addition, mRNA encoding SARS‐CoV‐2 Omicron receptor binding domain protein was synthesized, and intramuscular administration of mice with YK009‐LNP‐Omicron mRNA induced a robust immune response and immune protective effect. Our study provides a novel mRNA delivery vehicle with more powerful delivery efficiency and better safety than the approved LNPs. This article is protected by copyright. All rights reserved
nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials
What problem does this paper attempt to address?